SAB Biotherapeutics Inc (SABS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $266.66M
Last updated: Nov 17, 2026 at 11:05 AM ET
SAB Biotherapeutics Inc (SABS) Financials: Revenue, Profit and Cash Flow
SAB Biotherapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was $13.27M, operating cash flow was -$44.78M and free cash flow was -$45.71M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$22.30M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $48.95M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2024 | $1.32M | -40.9% | 100.0% | -3244.9% | -2579.0% |
| Dec 2023 | $2.24M | -90.6% | 100.0% | -1700.6% | -1884.5% |
| Dec 2022 | $23.90M | -60.7% | 100.0% | -121.0% | -78.4% |
| Dec 2021 | $60.88M | +10.2% | 100.0% | -22.0% | -28.2% |
| Dec 2020 | $55.24M | +1504.8% | 100.0% | 37.2% | 36.4% |
| Dec 2019 | $3.44M | N/A | 100.0% | -252.0% | -261.1% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.32M | $2.24M | $23.90M | $60.88M | $55.24M | $3.44M |
| Gross profit | $0 | $1.32M | $2.24M | $23.90M | $60.88M | $55.24M | $3.44M |
| Research and development | $34.35M | $30.25M | $16.52M | $36.44M | $57.18M | $27.91M | $8.02M |
| Operating income | -$48.95M | -$42.91M | -$38.08M | -$28.92M | -$13.39M | $20.56M | -$8.67M |
| Net income | $13.27M | -$34.11M | -$42.19M | -$18.74M | -$17.14M | $20.12M | -$8.99M |
| EBITDA | $15.08M | -$30.52M | N/A | -$15.19M | N/A | $21.10M | -$8.23M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $114.70K | $0 | $263.14K | $944.58K | $305.01K |
| Gross profit | $0 | $0 | $0 | -$763.30K | $0 | $0 | $0 | $114.70K | $0 | $263.14K | $944.58K | $305.01K |
| Operating income | -$25.90M | -$23.38M | -$20.00M | -$15.77M | -$12.68M | -$9.73M | -$10.77M | -$10.01M | -$11.31M | -$10.20M | -$11.39M | -$18.87M |
| Net income | -$22.30M | -$22.49M | -$18.87M | -$16.86M | $45.45M | -$10.11M | -$5.20M | -$11.39M | -$10.35M | -$7.34M | -$5.03M | -$22.86M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $0 by $10.50M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $172.81M | $44.20M | $83.94M | $50.90M | $81.14M | $56.54M | $18.00M |
| Current assets | $101.05M | $23.79M | $58.91M | $22.10M | $50.19M | $34.46M | $9.29M |
| Cash and equivalents | $10.50M | $8.90M | $56.57M | $15.05M | $33.21M | $12.61M | $6.35M |
| Total liabilities | $21.32M | $18.23M | $26.64M | $19.85M | $42.59M | $17.53M | $20.31M |
| Short-term debt | $0 | $275.85K | $1.05M | $772.66K | $1.80M | $538.73K | $1.95M |
| Long-term debt | N/A | N/A | N/A | $541.64K | $0 | $172.04K | $53.45K |
| Shareholder equity | $151.50M | $25.97M | $57.30M | $31.06M | $38.55M | $39.01M | -$2.31M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $235.64M | $238.21M | $248.47M | $172.81M | $183.45M | $30.13M | $38.12M | $44.20M | $53.80M | $61.89M | $71.37M | $83.94M |
| Total liabilities | $24.72M | $23.43M | $21.22M | $21.32M | $18.37M | $18.11M | $16.71M | $18.23M | $16.89M | $15.77M | $18.55M | $26.64M |
| Cash and equivalents | $14.44M | $8.27M | $20.52M | $10.50M | $29.42M | $3.69M | $5.64M | $8.90M | $9.17M | $17.24M | $14.03M | $56.57M |
| Shareholder equity | $210.92M | $214.78M | $227.25M | $151.49M | $165.07M | $12.02M | $21.41M | $25.97M | $36.90M | $46.12M | $52.82M | $57.30M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$44.78M | -$34.29M | -$25.12M | -$23.46M | $1.99M | $10.00M | -$9.21M |
| Capital expenditures | $933.16K | $337.26K | $197.15K | $2.17M | $10.94M | $12.73M | $608.75K |
| Free cash flow | -$45.71M | -$34.63M | -$25.32M | -$25.63M | -$8.96M | -$2.73M | -$9.82M |
| Investing cash flow | -$121.71M | -$11.96M | -$152.70K | -$2.09M | -$10.94M | -$12.72M | -$608.75K |
| Financing cash flow | $168.30M | -$1.17M | $66.77M | $1.05M | $35.89M | $8.98M | $3.68M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.02M | -$9.84M | -$14.27M | -$16.78M | -$13.05M | -$7.15M | -$7.80M | -$9.53M | -$6.29M | -$7.72M | -$10.75M | -$13.45M |
| Capital expenditures | $1.34M | $1.59M | $983.26K | $933.16K | $3 | $4 | $0 | $55.38K | $100.30K | $52.51K | $129.07K | $67.86K |
| Free cash flow | -$14.37M | -$11.43M | -$15.25M | -$17.71M | -$13.05M | -$7.15M | -$7.80M | -$9.59M | -$6.39M | -$7.77M | -$10.88M | -$13.51M |
Frequently Asked Questions About SABS
What is SAB Biotherapeutics' annual revenue?
SAB Biotherapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.
How fast is SAB Biotherapeutics' revenue growing?
Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is SAB Biotherapeutics profitable?
Yes. SAB Biotherapeutics reported net income of $13.27M for the fiscal year ended Dec 31, 2025.
How much free cash flow does SABS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$44.78M minus capital expenditures of $933.16K produced free cash flow of -$45.71M.
How much debt does SAB Biotherapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $0 and cash and equivalents of $10.50M.
SABS pages: Overview, Earnings, Forecast, Financials, Competitors